Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Biotherapics for Patients With Crohn's Disease

NCT03712826 · clinicaltrials.gov ↗

NA

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No inclusion

Conditions

Crohn Disease

Interventions

DRUG: Anti-TNF Drug
DRUG: Ustekinumab

Sponsor

Hospices Civils de Lyon